Research Article
BibTex RIS Cite

Sıçanlarda Bupropion ve Vareniklinin Morfin Yoksunluğu Sendromu Üzerine Etkileri

Year 2022, Volume: 11 Issue: 2, 231 - 242, 31.08.2022

Oruç Yunusoğlu Çagla Köse Andleeb Shahzadi Sibel Özyazgan Bülent Demir Burak Önal Ahmet Gökhan Akkan

https://doi.org/10.47493/abantmedj.1120849
Cited By: 1

Abstract

Amaç: Opioid bağımlılığı, nüks ve remisyon ile karakterize kronik ve karmaşık bir hastalıktır. Kronik morfin uygulaması, fiziksel ve psikolojik bağımlılık semptomlarına neden olur. Bu çalışmanın amacı, bupropion ve vareniklin gibi anti-bağımlılık ilaçlarının morfin bağımlılığı ve nalokson ile hızlanırılmış yoksunluk sendromu üzerindeki etkisini sıçan modelinde araştırmaktı.
Gereç ve Yöntemler: Morfine bağlı fiziksel bağımlılığı değerlendirmek için, yetişkin erkek Wistar sıçanlarına 5 gün boyunca günde iki kez artan dozlarda morfin intraperitoneal (i.p.) uygulandı. 6. günde tek doz morfin uygulamasından 4 saat sonra yoksunluk semptomlarını ortaya çıkarmak için subkutan (s.c.) nalokson (2 mg/kg, s.c.) uygulaması yapıldı. Fiziksel bağımlılık, 15 dakika süreyle intraperitoneal (i.p.) bupropion (5, 10 ve 20 mg/kg, i.p.) ve vareniklin (0,5, 1 ve 2 mg/kg, s.c) verilerek değerlendirildi.
Bulgular: Morfin gurubunda kontrol grubuna göre önemli ölçüde yoksunluk semptomları görüldü. Sonuçlar, morfin bağımlılığının indüklenmesi sırasında bupropion ve vareniklin uygulamasının, yoksunluk semptomlarının şiddetinin çoğunu azalttığını gösterdi. Bupropionun birlikte uygulanması, sıçrama, ıslak köpek silkelenmesi, kilo kaybı ve toplam yoksunluk semptomlarını azaltmıştır. Vareniklinin birlikte uygulanmasının bupropion gibi yoksunluk semptomları üzerinde etkili olduğu, ancak kilo kaybı üzerinde etkisi olmadığı saptandı.
Sonuç: Bu sonuçlar, bupropion ve vareniklinin morfininin yoksunluk semptomlarını hafifletmek için aday ilaçlar olarak kullanılabileceğine dair ön veriler sağlamaktadır.

Keywords

Morfin Bupropion Vareniklin Nalokson Opioid Yoksunluk Sendromu

References

  • 1. PERGOLIZZI J. V., JR., RAFFA R. B., ROSENBLATT M. H. Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: Current understanding and approaches to management, Journal of clinical pharmacy and therapeutics 2020: 45: 892-903.
  • 2. CANAMO L. J., TRONCO N. B. Clinical Opioid Withdrawal Scale (COWS): Implementation and Outcomes, Critical care nursing quarterly 2019: 42: 222-226.
  • 3. YUNUSOĞLU O. Rewarding effect of ethanol-induced conditioned place preference in mice: Effect of the monoterpenoid linalool, Alcohol (Fayetteville, NY) 2022: 98: 55-63.
  • 4. WANG S. Historical Review: Opiate Addiction and Opioid Receptors, Cell transplantation 2019: 28: 233-238.
  • 5. SRIVASTAVA A. B., MARIANI J. J., LEVIN F. R. New directions in the treatment of opioid withdrawal, Lancet (London, England) 2020: 395: 1938-1948.
  • 6. BELL J., STRANG J. Medication Treatment of Opioid Use Disorder, Biological psychiatry 2020: 87: 82-88.
  • 7. ALLAHVERDIYEV O., TÜRKMEN A. Z., NURTEN A., SEHIRLI I., ENGINAR N. Spontaneous withdrawal in intermittent morphine administration in rats and mice: effect of clonidine coadministration and sex-related differences, Turkish journal of medical sciences 2015: 45: 1380-1389.
  • 8. LISTOS J., ŁUPINA M., TALAREK S., MAZUR A., ORZELSKA-GÓRKA J., KOTLIŃSKA J. The Mechanisms Involved in Morphine Addiction: An Overview, International journal of molecular sciences 2019: 20.
  • 9. MAMALIGAS A. A., CAI Y., FORD C. P. Nicotinic and opioid receptor regulation of striatal dopamine D2-receptor mediated transmission, Scientific reports 2016: 6: 37834.
  • 10. ISE Y., NARITA M., NAGASE H., SUZUKI T. Modulation of kappa-opioidergic systems on mecamylamine-precipitated nicotine-withdrawal aversion in rats, Neuroscience letters 2002: 323: 164-166.
  • 11. YAMAMOTO A., KIGUCHI N., KOBAYASHI Y., MAEDA T., UENO K., YAMAMOTO C. et al. Pharmacological relationship between nicotinic and opioid systems in analgesia and corticosterone elevation, Life sciences 2011: 89: 956-961.
  • 12. REZAYOF A., ZATALI H., HAERI-ROHANI A., ZARRINDAST M. R. Dorsal hippocampal muscarinic and nicotinic receptors are involved in mediating morphine reward, Behavioural brain research 2006: 166: 281-290.
  • 13. DAVENPORT K. E., HOUDI A. A., VAN LOON G. R. Nicotine protects against mu-opioid receptor antagonism by beta-funaltrexamine: evidence for nicotine-induced release of endogenous opioids in brain, Neuroscience letters 1990: 113: 40-46.
  • 14. ISOLA R., ZHANG H., TEJWANI G. A., NEFF N. H., HADJICONSTANTINOU M. Acute nicotine changes dynorphin and prodynorphin mRNA in the striatum, Psychopharmacology 2009: 201: 507-516.
  • 15. ZARRINDAST M. R., FARZIN D. Nicotine attenuates naloxone-induced jumping behaviour in morphine-dependent mice, European journal of pharmacology 1996: 298: 1-6.
  • 16. SUH H. W., SONG D. K., CHOI S. R., CHUNG K. M., KIM Y. H. Nicotine enhances morphine- and beta-endorphin-induced antinociception at the supraspinal level in the mouse, Neuropeptides 1996: 30: 479-484.
  • 17. MCCLUNG C. A., NESTLER E. J., ZACHARIOU V. Regulation of gene expression by chronic morphine and morphine withdrawal in the locus ceruleus and ventral tegmental area, The Journal of neuroscience : the official journal of the Society for Neuroscience 2005: 25: 6005-6015.
  • 18. SCAVONE J. L., VAN BOCKSTAELE E. J. Mu-opioid receptor redistribution in the locus coeruleus upon precipitation of withdrawal in opiate-dependent rats, Anatomical record (Hoboken, NJ : 2007) 2009: 292: 401-411.
  • 19. FRYER J. D., LUKAS R. J. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine, The Journal of pharmacology and experimental therapeutics 1999: 288: 88-92.
  • 20. BUDZYŃSKA B., BIAŁA G. Effects of bupropion on the reinstatement of nicotine-induced conditioned place preference by drug priming in rats, Pharmacological reports : PR 2011: 63: 362-371.
  • 21. TRIVEDI M. H., WALKER R., LING W., DELA CRUZ A., SHARMA G., CARMODY T. et al. Bupropion and Naltrexone in Methamphetamine Use Disorder, The New England journal of medicine 2021: 384: 140-153.
  • 22. GLOVER E. D., GLOVER P. N. Pharmacologic treatments for the nicotine dependent smoker, American journal of health behavior 2001: 25: 179-182.
  • 23. DONG J., BLIER P. Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment, Psychopharmacology 2001: 155: 52-57.
  • 24. CRYAN J. F., O'LEARY O. F., JIN S. H., FRIEDLAND J. C., OUYANG M., HIRSCH B. R. et al. Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors, Proceedings of the National Academy of Sciences of the United States of America 2004: 101: 8186-8191.
  • 25. COOPER B. R., WANG C. M., COX R. F., NORTON R., SHEA V., FERRIS R. M. Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1994: 11: 133-141.
  • 26. GOLDEN R. N., DE VANE C. L., LAIZURE S. C., RUDORFER M. V., SHERER M. A., POTTER W. Z. Bupropion in depression. II. The role of metabolites in clinical outcome, Archives of general psychiatry 1988: 45: 145-149.
  • 27. NEWTON T. F., ROACHE J. D., DE LA GARZA R., 2ND, FONG T., WALLACE C. L., LI S. H. et al. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2006: 31: 1537-1544.
  • 28. ELKASHEF A. M., RAWSON R. A., ANDERSON A. L., LI S. H., HOLMES T., SMITH E. V. et al. Bupropion for the treatment of methamphetamine dependence, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2008: 33: 1162-1170.
  • 29. CARROLL F. I., BLOUGH B. E., ABRAHAM P., MILLS A. C., HOLLEMAN J. A., WOLCKENHAUER S. A. et al. Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction, Journal of medicinal chemistry 2009: 52: 6768-6781.
  • 30. REICHEL C. M., MURRAY J. E., GRANT K. M., BEVINS R. A. Bupropion attenuates methamphetamine self-administration in adult male rats, Drug and alcohol dependence 2009: 100: 54-62.
  • 31. PÉREZ-MAÑÁ C., CASTELLS X., TORRENS M., CAPELLÀ D., FARRE M. Efficacy of psychostimulant drugs for amphetamine abuse or dependence, The Cochrane database of systematic reviews 2013: Cd009695.
  • 32. TONSTAD S., ARONS C., ROLLEMA H., BERLIN I., HAJEK P., FAGERSTRÖM K. et al. Varenicline: mode of action, efficacy, safety and accumulated experience salient for clinical populations, Current medical research and opinion 2020: 36: 713-730.
  • 33. COE J. W., BROOKS P. R., VETELINO M. G., WIRTZ M. C., ARNOLD E. P., HUANG J. et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation, Journal of medicinal chemistry 2005: 48: 3474-3477.
  • 34. ROLLEMA H., CHAMBERS L. K., COE J. W., GLOWA J., HURST R. S., LEBEL L. A. et al. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid, Neuropharmacology 2007: 52: 985-994.
  • 35. MCCOLL S. L., BURSTEIN A. H., REEVES K. R., BILLING C. B., JR., STOLAR M., SELLERS E. M. Human abuse liability of the smoking cessation drug varenicline in smokers and nonsmokers, Clinical pharmacology and therapeutics 2008: 83: 607-614.
  • 36. WILLIAMS K. E., REEVES K. R., BILLING C. B., JR., PENNINGTON A. M., GONG J. A double-blind study evaluating the long-term safety of varenicline for smoking cessation, Current medical research and opinion 2007: 23: 793-801.
  • 37. BITO-ONON J. J., SIMMS J. A., CHATTERJEE S., HOLGATE J., BARTLETT S. E. Varenicline, a partial agonist at neuronal nicotinic acetylcholine receptors, reduces nicotine-induced increases in 20% ethanol operant self-administration in Sprague-Dawley rats, Addiction biology 2011: 16: 440-449.
  • 38. STEENSLAND P., SIMMS J. A., HOLGATE J., RICHARDS J. K., BARTLETT S. E. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking, Proceedings of the National Academy of Sciences of the United States of America 2007: 104: 12518-12523.
  • 39. WOUDA J. A., RIGA D., DE VRIES W., STEGEMAN M., VAN MOURIK Y., SCHETTERS D. et al. Varenicline attenuates cue-induced relapse to alcohol, but not nicotine seeking, while reducing inhibitory response control, Psychopharmacology 2011: 216: 267-277.
  • 40. HENDRICKSON L. M., ZHAO-SHEA R., PANG X., GARDNER P. D., TAPPER A. R. Activation of alpha4* nAChRs is necessary and sufficient for varenicline-induced reduction of alcohol consumption, The Journal of neuroscience : the official journal of the Society for Neuroscience 2010: 30: 10169-10176.
  • 41. KAMENS H. M., ANDERSEN J., PICCIOTTO M. R. Modulation of ethanol consumption by genetic and pharmacological manipulation of nicotinic acetylcholine receptors in mice, Psychopharmacology 2010: 208: 613-626.
  • 42. MCKEE S. A., HARRISON E. L., O'MALLEY S. S., KRISHNAN-SARIN S., SHI J., TETRAULT J. M. et al. Varenicline reduces alcohol self-administration in heavy-drinking smokers, Biological psychiatry 2009: 66: 185-190.
  • 43. MCRAE-CLARK A. L., GRAY K. M., BAKER N. L., SHERMAN B. J., SQUEGLIA L., SAHLEM G. L. et al. Varenicline as a treatment for cannabis use disorder: A placebo-controlled pilot trial, Drug and alcohol dependence 2021: 229: 109111.
  • 44. BIALA G., STANIAK N., BUDZYNSKA B. Effects of varenicline and mecamylamine on the acquisition, expression, and reinstatement of nicotine-conditioned place preference by drug priming in rats, Naunyn-Schmiedeberg's archives of pharmacology 2010: 381: 361-370.
  • 45. VAN DEN HOOGEN N. J., KWOK C. H. T., TRANG T. Identifying the Neurodevelopmental Differences of Opioid Withdrawal, Cellular and molecular neurobiology 2021: 41: 1145-1155.
  • 46. CHOU W. B., ZENG Y. M., DUAN S. M., ZHOU W. H., GU J., YANG G. D. M2 muscarinic receptor of spinal cord mediated increase of nNOS expression in locus coeruleus during morphine withdrawal, Acta pharmacologica Sinica 2002: 23: 691-697.
  • 47. BURNS J. A., KROLL D. S., FELDMAN D. E., KURE LIU C., MANZA P., WIERS C. E. et al. Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders, Frontiers in psychiatry 2019: 10: 626.
  • 48. HARRIS G. C., ASTON-JONES G. Involvement of D2 dopamine receptors in the nucleus accumbens in the opiate withdrawal syndrome, Nature 1994: 371: 155-157.
  • 49. NADER K., VAN DER KOOY D. Deprivation state switches the neurobiological substrates mediating opiate reward in the ventral tegmental area, The Journal of neuroscience : the official journal of the Society for Neuroscience 1997: 17: 383-390.
  • 50. KOSTEN T. R., GEORGE T. P. The neurobiology of opioid dependence: implications for treatment, Science & practice perspectives 2002: 1: 13-20.
  • 51. GEORGES F., ASTON-JONES G. Prolonged activation of mesolimbic dopaminergic neurons by morphine withdrawal following clonidine: participation of imidazoline and norepinephrine receptors, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2003: 28: 1140-1149.
  • 52. DIANA M., PISTIS M., MUNTONI A., GESSA G. Profound decrease of mesolimbic dopaminergic neuronal activity in morphine withdrawn rats, The Journal of pharmacology and experimental therapeutics 1995: 272: 781-785.
  • 53. GHOSH S., PATEL A. H., COUSINS M., GRASING K. Different effects of opiate withdrawal on dopamine turnover, uptake, and release in the striatum and nucleus accumbens, Neurochemical research 1998: 23: 875-885.
  • 54. JOSHI D., SINGH A., NAIDU P. S., KULKARNI S. K. Protective effect of bupropion on morphine tolerance and dependence in mice, Methods and findings in experimental and clinical pharmacology 2004: 26: 623-626.
  • 55. WALTERS C. L., ASTON-JONES G., DRUHAN J. P. Expression of fos-related antigens in the nucleus accumbens during opiate withdrawal and their attenuation by a D2 dopamine receptor agonist, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2000: 23: 307-315.
  • 56. ACQUAS E., CARBONI E., DI CHIARA G. Profound depression of mesolimbic dopamine release after morphine withdrawal in dependent rats, European journal of pharmacology 1991: 193: 133-134.
  • 57. CRIPPENS D., ROBINSON T. E. Withdrawal from morphine or amphetamine: different effects on dopamine in the ventral-medial striatum studied with microdialysis, Brain research 1994: 650: 56-62.
  • 58. SHAHAM Y., RAJABI H., STEWART J. Relapse to heroin-seeking in rats under opioid maintenance: the effects of stress, heroin priming, and withdrawal, The Journal of neuroscience : the official journal of the Society for Neuroscience 1996: 16: 1957-1963.
  • 59. MARTIN J. R., TAKEMORI A. E. Modification of the development of acute opiate tolerance by increased dopamine receptor sensitivity, The Journal of pharmacology and experimental therapeutics 1987: 241: 48-55.
  • 60. XUE Y., DOMINO E. F. Tobacco/nicotine and endogenous brain opioids, Progress in neuro-psychopharmacology & biological psychiatry 2008: 32: 1131-1138.
  • 61. ZARRINDAST M. R., BARGHI-LASHKARI S., SHAFIZADEH M. The possible cross-tolerance between morphine- and nicotine-induced hypothermia in mice, Pharmacology, biochemistry, and behavior 2001: 68: 283-289.
  • 62. ZARRINDAST M. R., KHOSHAYAND M. R., SHAFAGHI B. The development of cross-tolerance between morphine and nicotine in mice, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 1999: 9: 227-233.
  • 63. SHIPPENBERG T. S., HEIDBREDER C., LEFEVOUR A. Sensitization to the conditioned rewarding effects of morphine: pharmacology and temporal characteristics, European journal of pharmacology 1996: 299: 33-39.
  • 64. ISE Y., NARITA M., NAGASE H., SUZUKI T. Modulation of opioidergic system on mecamylamine-precipitated nicotine-withdrawal aversion in rats, Psychopharmacology 2000: 151: 49-54.
  • 65. HOUDI A. A., PIERZCHALA K., MARSON L., PALKOVITS M., VAN LOON G. R. Nicotine-induced alteration in Tyr-Gly-Gly and Met-enkephalin in discrete brain nuclei reflects altered enkephalin neuron activity, Peptides 1991: 12: 161-166.
  • 66. HOUDI A. A., DASGUPTA R., KINDY M. S. Effect of nicotine use and withdrawal on brain preproenkephalin A mRNA, Brain research 1998: 799: 257-263.
  • 67. WEWERS M. E., DHATT R. K., SNIVELY T. A., TEJWANI G. A. The effect of chronic administration of nicotine on antinociception, opioid receptor binding and met-enkelphalin levels in rats, Brain research 1999: 822: 107-113.
  • 68. MALIN D. H., LAKE J. R., CARTER V. A., CUNNINGHAM J. S., WILSON O. B. Naloxone precipitates nicotine abstinence syndrome in the rat, Psychopharmacology 1993: 112: 339-342.
  • 69. MALIN D. H., LAKE J. R., PAYNE M. C., SHORT P. E., CARTER V. A., CUNNINGHAM J. S. et al. Nicotine alleviation of nicotine abstinence syndrome is naloxone-reversible, Pharmacology, biochemistry, and behavior 1996: 53: 81-85.

The Effects of Bupropion and Varenicline on Morphine Withdrawal Syndrome in Rats

Year 2022, Volume: 11 Issue: 2, 231 - 242, 31.08.2022

Oruç Yunusoğlu Çagla Köse Andleeb Shahzadi Sibel Özyazgan Bülent Demir Burak Önal Ahmet Gökhan Akkan

https://doi.org/10.47493/abantmedj.1120849
Cited By: 1

Abstract

Objective: Opioid dependence is a chronic complicated disorder characterized by relapse and remission. Chronic administration of morphine causes symptoms of physical and psychological dependence. The purpose of the present study was to investigate the effect of anti-addictive drugs such as bupropion and varenicline on morphine dependence and naloxone precipitated withdrawal syndrome in a rat model.
Materials and Methods: To assess the physical dependence of morphine, adult male Wistar rats were administered intraperitoneally (i.p.) increasing doses of morphine twice daily for 5 days, 4 hours after a single dose of morphine on day 6, and 15 minutes before subcutaneous (s.c.) naloxone (2 mg/kg, s.c.) administration to elicit withdrawal symptoms. Physical dependence was evaluated by injecting bupropion (5, 10, and 20 mg/kg, i.p.) and varenicline (0.5. 1, and 2 mg/kg, s.c.) for 15 minutes.
Results: The morphine-dependent rats more significantly demonstrated withdrawal symptoms than naive control rats. The results elucidated that administration of bupropion and varenicline during induction of morphine dependence attenuated the most of the severity of withdrawal symptoms. Co-administration of bupropion with morphine reduced withdrawal symptoms such as jumping, wet dog shaking, weight loss and total withdrawal symptoms. Co-administration of varenicline with morphine was found to be effective on withdrawal symptoms such as bupropion, but had no effect on weight loss.
Conclusion: These outcomes provide preliminary data which show that bupropion and varenicline can be used as a candidate drugs to attenuate morphine withdrawal symptoms.

Keywords

Morfin Bupropion Vareniklin Nalokson Opioid Yoksunluk Sendromu

References

  • 1. PERGOLIZZI J. V., JR., RAFFA R. B., ROSENBLATT M. H. Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: Current understanding and approaches to management, Journal of clinical pharmacy and therapeutics 2020: 45: 892-903.
  • 2. CANAMO L. J., TRONCO N. B. Clinical Opioid Withdrawal Scale (COWS): Implementation and Outcomes, Critical care nursing quarterly 2019: 42: 222-226.
  • 3. YUNUSOĞLU O. Rewarding effect of ethanol-induced conditioned place preference in mice: Effect of the monoterpenoid linalool, Alcohol (Fayetteville, NY) 2022: 98: 55-63.
  • 4. WANG S. Historical Review: Opiate Addiction and Opioid Receptors, Cell transplantation 2019: 28: 233-238.
  • 5. SRIVASTAVA A. B., MARIANI J. J., LEVIN F. R. New directions in the treatment of opioid withdrawal, Lancet (London, England) 2020: 395: 1938-1948.
  • 6. BELL J., STRANG J. Medication Treatment of Opioid Use Disorder, Biological psychiatry 2020: 87: 82-88.
  • 7. ALLAHVERDIYEV O., TÜRKMEN A. Z., NURTEN A., SEHIRLI I., ENGINAR N. Spontaneous withdrawal in intermittent morphine administration in rats and mice: effect of clonidine coadministration and sex-related differences, Turkish journal of medical sciences 2015: 45: 1380-1389.
  • 8. LISTOS J., ŁUPINA M., TALAREK S., MAZUR A., ORZELSKA-GÓRKA J., KOTLIŃSKA J. The Mechanisms Involved in Morphine Addiction: An Overview, International journal of molecular sciences 2019: 20.
  • 9. MAMALIGAS A. A., CAI Y., FORD C. P. Nicotinic and opioid receptor regulation of striatal dopamine D2-receptor mediated transmission, Scientific reports 2016: 6: 37834.
  • 10. ISE Y., NARITA M., NAGASE H., SUZUKI T. Modulation of kappa-opioidergic systems on mecamylamine-precipitated nicotine-withdrawal aversion in rats, Neuroscience letters 2002: 323: 164-166.
  • 11. YAMAMOTO A., KIGUCHI N., KOBAYASHI Y., MAEDA T., UENO K., YAMAMOTO C. et al. Pharmacological relationship between nicotinic and opioid systems in analgesia and corticosterone elevation, Life sciences 2011: 89: 956-961.
  • 12. REZAYOF A., ZATALI H., HAERI-ROHANI A., ZARRINDAST M. R. Dorsal hippocampal muscarinic and nicotinic receptors are involved in mediating morphine reward, Behavioural brain research 2006: 166: 281-290.
  • 13. DAVENPORT K. E., HOUDI A. A., VAN LOON G. R. Nicotine protects against mu-opioid receptor antagonism by beta-funaltrexamine: evidence for nicotine-induced release of endogenous opioids in brain, Neuroscience letters 1990: 113: 40-46.
  • 14. ISOLA R., ZHANG H., TEJWANI G. A., NEFF N. H., HADJICONSTANTINOU M. Acute nicotine changes dynorphin and prodynorphin mRNA in the striatum, Psychopharmacology 2009: 201: 507-516.
  • 15. ZARRINDAST M. R., FARZIN D. Nicotine attenuates naloxone-induced jumping behaviour in morphine-dependent mice, European journal of pharmacology 1996: 298: 1-6.
  • 16. SUH H. W., SONG D. K., CHOI S. R., CHUNG K. M., KIM Y. H. Nicotine enhances morphine- and beta-endorphin-induced antinociception at the supraspinal level in the mouse, Neuropeptides 1996: 30: 479-484.
  • 17. MCCLUNG C. A., NESTLER E. J., ZACHARIOU V. Regulation of gene expression by chronic morphine and morphine withdrawal in the locus ceruleus and ventral tegmental area, The Journal of neuroscience : the official journal of the Society for Neuroscience 2005: 25: 6005-6015.
  • 18. SCAVONE J. L., VAN BOCKSTAELE E. J. Mu-opioid receptor redistribution in the locus coeruleus upon precipitation of withdrawal in opiate-dependent rats, Anatomical record (Hoboken, NJ : 2007) 2009: 292: 401-411.
  • 19. FRYER J. D., LUKAS R. J. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine, The Journal of pharmacology and experimental therapeutics 1999: 288: 88-92.
  • 20. BUDZYŃSKA B., BIAŁA G. Effects of bupropion on the reinstatement of nicotine-induced conditioned place preference by drug priming in rats, Pharmacological reports : PR 2011: 63: 362-371.
  • 21. TRIVEDI M. H., WALKER R., LING W., DELA CRUZ A., SHARMA G., CARMODY T. et al. Bupropion and Naltrexone in Methamphetamine Use Disorder, The New England journal of medicine 2021: 384: 140-153.
  • 22. GLOVER E. D., GLOVER P. N. Pharmacologic treatments for the nicotine dependent smoker, American journal of health behavior 2001: 25: 179-182.
  • 23. DONG J., BLIER P. Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment, Psychopharmacology 2001: 155: 52-57.
  • 24. CRYAN J. F., O'LEARY O. F., JIN S. H., FRIEDLAND J. C., OUYANG M., HIRSCH B. R. et al. Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors, Proceedings of the National Academy of Sciences of the United States of America 2004: 101: 8186-8191.
  • 25. COOPER B. R., WANG C. M., COX R. F., NORTON R., SHEA V., FERRIS R. M. Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1994: 11: 133-141.
  • 26. GOLDEN R. N., DE VANE C. L., LAIZURE S. C., RUDORFER M. V., SHERER M. A., POTTER W. Z. Bupropion in depression. II. The role of metabolites in clinical outcome, Archives of general psychiatry 1988: 45: 145-149.
  • 27. NEWTON T. F., ROACHE J. D., DE LA GARZA R., 2ND, FONG T., WALLACE C. L., LI S. H. et al. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2006: 31: 1537-1544.
  • 28. ELKASHEF A. M., RAWSON R. A., ANDERSON A. L., LI S. H., HOLMES T., SMITH E. V. et al. Bupropion for the treatment of methamphetamine dependence, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2008: 33: 1162-1170.
  • 29. CARROLL F. I., BLOUGH B. E., ABRAHAM P., MILLS A. C., HOLLEMAN J. A., WOLCKENHAUER S. A. et al. Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction, Journal of medicinal chemistry 2009: 52: 6768-6781.
  • 30. REICHEL C. M., MURRAY J. E., GRANT K. M., BEVINS R. A. Bupropion attenuates methamphetamine self-administration in adult male rats, Drug and alcohol dependence 2009: 100: 54-62.
  • 31. PÉREZ-MAÑÁ C., CASTELLS X., TORRENS M., CAPELLÀ D., FARRE M. Efficacy of psychostimulant drugs for amphetamine abuse or dependence, The Cochrane database of systematic reviews 2013: Cd009695.
  • 32. TONSTAD S., ARONS C., ROLLEMA H., BERLIN I., HAJEK P., FAGERSTRÖM K. et al. Varenicline: mode of action, efficacy, safety and accumulated experience salient for clinical populations, Current medical research and opinion 2020: 36: 713-730.
  • 33. COE J. W., BROOKS P. R., VETELINO M. G., WIRTZ M. C., ARNOLD E. P., HUANG J. et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation, Journal of medicinal chemistry 2005: 48: 3474-3477.
  • 34. ROLLEMA H., CHAMBERS L. K., COE J. W., GLOWA J., HURST R. S., LEBEL L. A. et al. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid, Neuropharmacology 2007: 52: 985-994.
  • 35. MCCOLL S. L., BURSTEIN A. H., REEVES K. R., BILLING C. B., JR., STOLAR M., SELLERS E. M. Human abuse liability of the smoking cessation drug varenicline in smokers and nonsmokers, Clinical pharmacology and therapeutics 2008: 83: 607-614.
  • 36. WILLIAMS K. E., REEVES K. R., BILLING C. B., JR., PENNINGTON A. M., GONG J. A double-blind study evaluating the long-term safety of varenicline for smoking cessation, Current medical research and opinion 2007: 23: 793-801.
  • 37. BITO-ONON J. J., SIMMS J. A., CHATTERJEE S., HOLGATE J., BARTLETT S. E. Varenicline, a partial agonist at neuronal nicotinic acetylcholine receptors, reduces nicotine-induced increases in 20% ethanol operant self-administration in Sprague-Dawley rats, Addiction biology 2011: 16: 440-449.
  • 38. STEENSLAND P., SIMMS J. A., HOLGATE J., RICHARDS J. K., BARTLETT S. E. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking, Proceedings of the National Academy of Sciences of the United States of America 2007: 104: 12518-12523.
  • 39. WOUDA J. A., RIGA D., DE VRIES W., STEGEMAN M., VAN MOURIK Y., SCHETTERS D. et al. Varenicline attenuates cue-induced relapse to alcohol, but not nicotine seeking, while reducing inhibitory response control, Psychopharmacology 2011: 216: 267-277.
  • 40. HENDRICKSON L. M., ZHAO-SHEA R., PANG X., GARDNER P. D., TAPPER A. R. Activation of alpha4* nAChRs is necessary and sufficient for varenicline-induced reduction of alcohol consumption, The Journal of neuroscience : the official journal of the Society for Neuroscience 2010: 30: 10169-10176.
  • 41. KAMENS H. M., ANDERSEN J., PICCIOTTO M. R. Modulation of ethanol consumption by genetic and pharmacological manipulation of nicotinic acetylcholine receptors in mice, Psychopharmacology 2010: 208: 613-626.
  • 42. MCKEE S. A., HARRISON E. L., O'MALLEY S. S., KRISHNAN-SARIN S., SHI J., TETRAULT J. M. et al. Varenicline reduces alcohol self-administration in heavy-drinking smokers, Biological psychiatry 2009: 66: 185-190.
  • 43. MCRAE-CLARK A. L., GRAY K. M., BAKER N. L., SHERMAN B. J., SQUEGLIA L., SAHLEM G. L. et al. Varenicline as a treatment for cannabis use disorder: A placebo-controlled pilot trial, Drug and alcohol dependence 2021: 229: 109111.
  • 44. BIALA G., STANIAK N., BUDZYNSKA B. Effects of varenicline and mecamylamine on the acquisition, expression, and reinstatement of nicotine-conditioned place preference by drug priming in rats, Naunyn-Schmiedeberg's archives of pharmacology 2010: 381: 361-370.
  • 45. VAN DEN HOOGEN N. J., KWOK C. H. T., TRANG T. Identifying the Neurodevelopmental Differences of Opioid Withdrawal, Cellular and molecular neurobiology 2021: 41: 1145-1155.
  • 46. CHOU W. B., ZENG Y. M., DUAN S. M., ZHOU W. H., GU J., YANG G. D. M2 muscarinic receptor of spinal cord mediated increase of nNOS expression in locus coeruleus during morphine withdrawal, Acta pharmacologica Sinica 2002: 23: 691-697.
  • 47. BURNS J. A., KROLL D. S., FELDMAN D. E., KURE LIU C., MANZA P., WIERS C. E. et al. Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders, Frontiers in psychiatry 2019: 10: 626.
  • 48. HARRIS G. C., ASTON-JONES G. Involvement of D2 dopamine receptors in the nucleus accumbens in the opiate withdrawal syndrome, Nature 1994: 371: 155-157.
  • 49. NADER K., VAN DER KOOY D. Deprivation state switches the neurobiological substrates mediating opiate reward in the ventral tegmental area, The Journal of neuroscience : the official journal of the Society for Neuroscience 1997: 17: 383-390.
  • 50. KOSTEN T. R., GEORGE T. P. The neurobiology of opioid dependence: implications for treatment, Science & practice perspectives 2002: 1: 13-20.
  • 51. GEORGES F., ASTON-JONES G. Prolonged activation of mesolimbic dopaminergic neurons by morphine withdrawal following clonidine: participation of imidazoline and norepinephrine receptors, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2003: 28: 1140-1149.
  • 52. DIANA M., PISTIS M., MUNTONI A., GESSA G. Profound decrease of mesolimbic dopaminergic neuronal activity in morphine withdrawn rats, The Journal of pharmacology and experimental therapeutics 1995: 272: 781-785.
  • 53. GHOSH S., PATEL A. H., COUSINS M., GRASING K. Different effects of opiate withdrawal on dopamine turnover, uptake, and release in the striatum and nucleus accumbens, Neurochemical research 1998: 23: 875-885.
  • 54. JOSHI D., SINGH A., NAIDU P. S., KULKARNI S. K. Protective effect of bupropion on morphine tolerance and dependence in mice, Methods and findings in experimental and clinical pharmacology 2004: 26: 623-626.
  • 55. WALTERS C. L., ASTON-JONES G., DRUHAN J. P. Expression of fos-related antigens in the nucleus accumbens during opiate withdrawal and their attenuation by a D2 dopamine receptor agonist, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2000: 23: 307-315.
  • 56. ACQUAS E., CARBONI E., DI CHIARA G. Profound depression of mesolimbic dopamine release after morphine withdrawal in dependent rats, European journal of pharmacology 1991: 193: 133-134.
  • 57. CRIPPENS D., ROBINSON T. E. Withdrawal from morphine or amphetamine: different effects on dopamine in the ventral-medial striatum studied with microdialysis, Brain research 1994: 650: 56-62.
  • 58. SHAHAM Y., RAJABI H., STEWART J. Relapse to heroin-seeking in rats under opioid maintenance: the effects of stress, heroin priming, and withdrawal, The Journal of neuroscience : the official journal of the Society for Neuroscience 1996: 16: 1957-1963.
  • 59. MARTIN J. R., TAKEMORI A. E. Modification of the development of acute opiate tolerance by increased dopamine receptor sensitivity, The Journal of pharmacology and experimental therapeutics 1987: 241: 48-55.
  • 60. XUE Y., DOMINO E. F. Tobacco/nicotine and endogenous brain opioids, Progress in neuro-psychopharmacology & biological psychiatry 2008: 32: 1131-1138.
  • 61. ZARRINDAST M. R., BARGHI-LASHKARI S., SHAFIZADEH M. The possible cross-tolerance between morphine- and nicotine-induced hypothermia in mice, Pharmacology, biochemistry, and behavior 2001: 68: 283-289.
  • 62. ZARRINDAST M. R., KHOSHAYAND M. R., SHAFAGHI B. The development of cross-tolerance between morphine and nicotine in mice, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 1999: 9: 227-233.
  • 63. SHIPPENBERG T. S., HEIDBREDER C., LEFEVOUR A. Sensitization to the conditioned rewarding effects of morphine: pharmacology and temporal characteristics, European journal of pharmacology 1996: 299: 33-39.
  • 64. ISE Y., NARITA M., NAGASE H., SUZUKI T. Modulation of opioidergic system on mecamylamine-precipitated nicotine-withdrawal aversion in rats, Psychopharmacology 2000: 151: 49-54.
  • 65. HOUDI A. A., PIERZCHALA K., MARSON L., PALKOVITS M., VAN LOON G. R. Nicotine-induced alteration in Tyr-Gly-Gly and Met-enkephalin in discrete brain nuclei reflects altered enkephalin neuron activity, Peptides 1991: 12: 161-166.
  • 66. HOUDI A. A., DASGUPTA R., KINDY M. S. Effect of nicotine use and withdrawal on brain preproenkephalin A mRNA, Brain research 1998: 799: 257-263.
  • 67. WEWERS M. E., DHATT R. K., SNIVELY T. A., TEJWANI G. A. The effect of chronic administration of nicotine on antinociception, opioid receptor binding and met-enkelphalin levels in rats, Brain research 1999: 822: 107-113.
  • 68. MALIN D. H., LAKE J. R., CARTER V. A., CUNNINGHAM J. S., WILSON O. B. Naloxone precipitates nicotine abstinence syndrome in the rat, Psychopharmacology 1993: 112: 339-342.
  • 69. MALIN D. H., LAKE J. R., PAYNE M. C., SHORT P. E., CARTER V. A., CUNNINGHAM J. S. et al. Nicotine alleviation of nicotine abstinence syndrome is naloxone-reversible, Pharmacology, biochemistry, and behavior 1996: 53: 81-85.
There are 69 citations in total.

Details

Primary Language English
Subjects Clinical Sciences
Journal Section Research Articles
Authors

Oruç Yunusoğlu 0000-0003-1075-9574

Çagla Köse 0000-0002-3298-6746

Andleeb Shahzadi 0000-0002-2774-2325

Sibel Özyazgan 0000-0002-2511-3541

Bülent Demir 0000-0003-1767-408X

Burak Önal 0000-0002-7846-875X

Ahmet Gökhan Akkan 0000-0002-6799-1721

Publication Date August 31, 2022
Submission Date May 30, 2022
Published in Issue Year 2022 Volume: 11 Issue: 2

Cite

APA Yunusoğlu, O., Köse, Ç., Shahzadi, A., Özyazgan, S., et al. (2022). The Effects of Bupropion and Varenicline on Morphine Withdrawal Syndrome in Rats. Abant Medical Journal, 11(2), 231-242. https://doi.org/10.47493/abantmedj.1120849
AMA Yunusoğlu O, Köse Ç, Shahzadi A, Özyazgan S, Demir B, Önal B, Akkan AG. The Effects of Bupropion and Varenicline on Morphine Withdrawal Syndrome in Rats. Abant Med J. August 2022;11(2):231-242. doi:10.47493/abantmedj.1120849
Chicago Yunusoğlu, Oruç, Çagla Köse, Andleeb Shahzadi, Sibel Özyazgan, Bülent Demir, Burak Önal, and Ahmet Gökhan Akkan. “The Effects of Bupropion and Varenicline on Morphine Withdrawal Syndrome in Rats”. Abant Medical Journal 11, no. 2 (August 2022): 231-42. https://doi.org/10.47493/abantmedj.1120849.
EndNote Yunusoğlu O, Köse Ç, Shahzadi A, Özyazgan S, Demir B, Önal B, Akkan AG (August 1, 2022) The Effects of Bupropion and Varenicline on Morphine Withdrawal Syndrome in Rats. Abant Medical Journal 11 2 231–242.
IEEE O. Yunusoğlu, “The Effects of Bupropion and Varenicline on Morphine Withdrawal Syndrome in Rats”, Abant Med J, vol. 11, no. 2, pp. 231–242, 2022, doi: 10.47493/abantmedj.1120849.
ISNAD Yunusoğlu, Oruç et al. “The Effects of Bupropion and Varenicline on Morphine Withdrawal Syndrome in Rats”. Abant Medical Journal 11/2 (August 2022), 231-242. https://doi.org/10.47493/abantmedj.1120849.
JAMA Yunusoğlu O, Köse Ç, Shahzadi A, Özyazgan S, Demir B, Önal B, Akkan AG. The Effects of Bupropion and Varenicline on Morphine Withdrawal Syndrome in Rats. Abant Med J. 2022;11:231–242.
MLA Yunusoğlu, Oruç et al. “The Effects of Bupropion and Varenicline on Morphine Withdrawal Syndrome in Rats”. Abant Medical Journal, vol. 11, no. 2, 2022, pp. 231-42, doi:10.47493/abantmedj.1120849.
Vancouver Yunusoğlu O, Köse Ç, Shahzadi A, Özyazgan S, Demir B, Önal B, Akkan AG. The Effects of Bupropion and Varenicline on Morphine Withdrawal Syndrome in Rats. Abant Med J. 2022;11(2):231-42.

Cited By

Multi-view image-based behavior classification of wet-dog shake in Kainate rat model
Frontiers in Behavioral Neuroscience
https://doi.org/10.3389/fnbeh.2023.1148549
 Download Cover Image